MediMabBio
Latest round
- Series B
Last raised
- Oct 2025
Total raised
- $34M
Investors
- 18
About MediMabBio
Founded in 2017, and based in Seongnam, South Korea, MediMabBio Inc. operates as a biotechnology firm that develops drugs and immunotherapies to treat patients with cancer. In October 2025, MediMabBio Inc., KNOTUS, KB Investment, Smilegate Investment, BNH Investment, Hyundai Investment Partners, iM Investment Partners, and Timefolio Asset Management. MediMabBio Inc. is a healthcare immunotherapy developer that intends to fight cancer by utilizing the power of modern biology and advanced immunological techniques. The company's primary goal is to develop effective first-in-class immuno-oncology medications capable of targeting a range of advanced and solid tumors. By doing so, they hope to overcome the current limitations of cancer immunotherapy and provide new treatment options for cancer patients. The company will use the investment in October 2025 to further accelerate the development and commercialization of next-generation immunotherapies to the global market.
Who invested in MediMabBio
18 investors across 2 rounds
See all investors in MediMabBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about MediMabBio
Who invested in MediMabBio?
MediMabBio has 18 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MediMabBio raised?
MediMabBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did MediMabBio last raise money?
MediMabBio's most recent round on record is a Series B, in Oct 2025.
What does MediMabBio do?
Founded in 2017, and based in Seongnam, South Korea, MediMabBio Inc.
Where is MediMabBio headquartered?
MediMabBio is headquartered in Seongnam, South Korea.
Which VCs invest in companies like MediMabBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at MediMabBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like MediMabBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.